The abstract is read at the publisher; the summary is JClub's.
In LIBREXIA-ACS, milvexian added after acute coronary syndrome did not reduce cardiovascular death, myocardial infarction, or ischemic stroke, and showed no intracranial or fatal bleeding increase.
- Why it matters: The trial addresses whether factor XIa inhibition meaningfully improves outcomes in arterial thrombosis after acute coronary syndrome, despite uncertainty about how factor XI contributes across indications.
- What they did: Milvexian was tested as an add-on to antiplatelet therapy in a LIBREXIA-ACS study that was terminated early for futility, assessing cardiovascular death, myocardial infarction, ischemic stroke, and bleeding outcomes.
- The result: The findings suggest factor XIa inhibition may not provide benefit in this acute coronary syndrome population, while highlighting the need to optimize inhibitor choice, dosing, and patient selection.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.